Secondary Logo

Most Popular Articles

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections

Hamadeh, Issam S.; Klinker, Kenneth P.; Borgert, Samuel J.; More

Pharmacogenetics and Genomics. 27(5):190-196, May 2017.

CYP2C9 variants as a risk modifier of NSAID-related gastrointestinal bleeding: a case–control study

Figueiras, Adolfo; Estany-Gestal, Ana; Aguirre, Carmelo; More

Pharmacogenetics and Genomics. 26(2):66-73, February 2016.

Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in Aborigines from Western Australia

Griese, Ernst-Ulrich; Ilett, Kenneth F.; Kitteringham, Neil R.; More

Pharmacogenetics. 11(1):69-76, February 2001.

Characterization of ADME gene variation in 21 populations by exome sequencing

Hovelson, Daniel H.; Xue, Zhengyu; Zawistowski, Matthew; More

Pharmacogenetics and Genomics. 27(3):89-100, March 2017.

Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics

Chan, Sze Ling; Samaranayake, Nilakshi; Ross, Colin J.D.; More

Pharmacogenetics and Genomics. 26(1):28-39, January 2016.

Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients

Allegra, Sarah; Cusato, Jessica; De Francia, Silvia; More

Pharmacogenetics and Genomics. 28(9):199-206, September 2018.

Pharmacogenetic variants and response to neoadjuvant single-agent doxorubicin or docetaxel: a study in locally advanced breast cancer patients participating in the NCT00123929 phase 2 randomized trial

Ruiz-Pinto, Sara; Martin, Miguel; Pita, Guillermo; More

Pharmacogenetics and Genomics. 28(11):245-250, November 2018.

The common Arg389gly ADRB1 polymorphism affects heart rate response to the ultra-short-acting β1 adrenergic receptor antagonist esmolol in healthy individuals

Muszkat, Mordechai; Hoofien, Assaf; Orlanski-Meyer, Esther; More

Pharmacogenetics and Genomics. 23(1):25-28, January 2013.

A genetic variant in NRP1 is associated with worse response to ranibizumab treatment in neovascular age-related macular degeneration

Lorés-Motta, Laura; van Asten, Freekje; Muether, Philipp S.; More

Pharmacogenetics and Genomics. 26(1):20-27, January 2016.

In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics

Tang, Cuyue; Shou, Magang; Rushmore, Thomas H.; More

Pharmacogenetics. 11(3):223-235, April 2001.

Identification and functional characterization of eight CYP3A4 protein variants

Eiselt, Regina; Domanski, Tammy L.; Zibat, Arne; More

Pharmacogenetics. 11(5):447-458, July 2001.

Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism

Schwab, Matthias; Schäffeler, Elke; Marx, Claudia; More

Pharmacogenetics. 12(6):429-436, August 2002.

Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications

Creemer, Olivia J.; Ansari-Pour, Naser; Ekong, Rosemary; More

Pharmacogenetics and Genomics. 26(6):255-270, June 2016.

Assessment of provider-perceived barriers to clinical use of pharmacogenomics during participation in an institutional implementation study

Borden, Brittany A.; Galecki, Paige; Wellmann, Rebecca; More

Pharmacogenetics and Genomics. 29(2):31-38, February 2019.

The role of genetic polymorphisms in the thymidylate synthase (TYMS) gene in methotrexate-induced oral mucositis in children with acute lymphoblastic leukemia

Oosterom, Natanja; Berrevoets, Marijn; den Hoed, Marissa A.H.; More

Pharmacogenetics and Genomics. 28(10):223-229, October 2018.

The genetic determinants of the CYP3A5 polymorphism

Hustert, Elisabeth; Haberl, Michael; Burk, Oliver; More

Pharmacogenetics. 11(9):773-779, December 2001.

Interleukin-1B genotype modulates the improvement of coronary artery reactivity by lipid-lowering therapy with pravastatin: a placebo-controlled positron emission tomography study in young healthy men

Lehtimäki, Terho; Laaksonen, Reijo; Janatuinen, Tuula; More

Pharmacogenetics. 13(10):633-639, October 2003.

Characterization of the monomethylarsonate reductase and dehydroascorbate reductase activities of Omega class glutathione transferase variants: implications for arsenic metabolism and the age-at-onset of Alzheimer's and Parkinson's diseases

Schmuck, Erica M.; Board, Philip G.; Whitbread, Astrid K.; More

Pharmacogenetics and Genomics. 15(7):493-501, July 2005.

Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy

Collins, Kimberly S.; Pratt, Victoria M.; Stansberry, Wesley M.; More

Pharmacogenetics and Genomics. 29(1):18-22, January 2019.

International survey of patients undergoing percutaneous coronary intervention and their attitudes toward pharmacogenetic testing

Pereira, Naveen L.; So, Derek; Bae, Jang-Ho; More

Pharmacogenetics and Genomics. 29(4):76-83, June 2019.

Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions

Hung, Shuen-Iu; Chung, Wen-Hung; Jee, Shiou-Hwa; More

Pharmacogenetics and Genomics. 16(4):297-306, April 2006.

Evaluation of KDR rs34231037 as a predictor of sunitinib efficacy in patients with metastatic renal cell carcinoma

Apellániz-Ruiz, María; Diekstra, Meta H.; Roldán, Juan M.; More

Pharmacogenetics and Genomics. 27(6):227-231, June 2017.

Influence of microsomal triglyceride transfer protein promoter polymorphism −493 GT on fasting plasma triglyceride values and interaction with treatment response to atorvastatin in subjects with heterozygous familial hypercholesterolaemia

García-García, Ana B.; González, Cintia; Real, José T.; More

Pharmacogenetics and Genomics. 15(4):211-218, April 2005.

Leveraging electronic health records to assess the role of ADRB2 single nucleotide polymorphisms in predicting exacerbation frequency in asthma patients

Sood, Nikita; Connolly, John J.; Mentch, Frank D.; More

Pharmacogenetics and Genomics. 28(11):256-259, November 2018.

Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan

Kühne, Annett; Kaiser, Rolf; Schirmer, Markus; More

Pharmacogenetics and Genomics. 17(7):505-517, July 2007.

Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz

Klein, Kathrin; Lang, Thomas; Saussele, Tanja; More

Pharmacogenetics and Genomics. 15(12):861-873, December 2005.

CYP2D6 function moderates the pharmacokinetics and pharmacodynamics of 3,4-methylene-dioxymethamphetamine in a controlled study in healthy individuals

Schmid, Yasmin; Vizeli, Patrick; Hysek, Cédric M.; More

Pharmacogenetics and Genomics. 26(8):397-401, August 2016.